Answers are grounded in this paper and cite their sources.
The synthesis of the tetracosapeptide β 1–24 ‐corticotropin, containing the N‐terminal 24 amino‐acid residues of β‐corticotropin (ACTH) 2 ), is described in detail. Many intermediates, including derivatives of the decapeptide β 1–10 ‐corticotropin and of the tetradecapeptide β 11–24 ‐corticotropin, were obtained in the cristalline state. A new scheme for the protection of amino and carboxyl groups in the side chains of amino‐acid residues was developed: this led to a blocked tetracosapeptide II which contains only protective groups derived from t ‐butanol. These may be removed quantitatively, without formation of side‐products. β 1–24 ‐Corticotropin (I) is thus obtained directly in an analytically pure state; [α] 25 = − 88,6 ± 2° (c = 0,5 in 1 per cent acetic acid). The biological activity of the product was found to be 106 ± 14 USP‐U/mg (ACTH). It is equally active on intravenous application in human beings.
No takes yet. Share an insight, caveat, or question.
Schwyzer et al. (1963) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: